Why the study?
TDI-MPI predicts cardiovascular mortality in adults, but data on its use and prognostic significance in children with dilated cardiomyopathy are lacking.
Does tissue Doppler imaging-derived myocardial performance index (TDI-MPI) at diagnosis predict the composite outcome of death, VAD, or transplant in pediatric patients with dilated cardiomyopathy?
Does tissue Doppler imaging-derived myocardial performance index (TDI-MPI) at diagnosis predict the composite outcome of death, VAD, or transplant in pediatric patients with dilated cardiomyopathy?
A TDI-MPI z-score ≥2 at the time of diagnosis is a significant predictor of death, VAD placement, or cardiac transplant in pediatric patients with dilated cardiomyopathy.
TDI-MPI has been shown to predict cardiovascular mortality in adults; there are a paucity of data on its use in children. We sought to determine the prognostic significance of TDI-MPI at time of DCM diagnosis in children. Patients aged ≤18 years diagnosed with DCM were included along with age- and sex-matched controls. Echo at diagnosis was analyzed to obtain standard measures of LV function, PW-MPI, and septal and LV free wall TDI-MPI. Survival analysis was used to assess the time to composite outcome of death, VAD, or transplant, stratified by TDI-MPI z-score. The study included 79 patients with DCM and 79 controls. During a median follow-up of 182 days (IQR 41-815 days), 16 underwent VAD placement, 21 underwent cardiac transplant, 6 died, and 36 had event-free survival. The median septal TDI-MPI for cases was 0.70 for patients with DCM vs 0.45 for controls (P < .001). Those with septal TDI-MPI z-scores ≥2 develop events significantly earlier than those with z-score <2 (P = .014). In multivariable analysis, TDI-MPI z-score ≥2 was significantly associated with poor outcomes (HR 2.12, 95% CI 1.06-4.23). TDI-MPI can be reliably performed in pediatric patients with DCM. A TDI-MPI z-score ≥2 at diagnosis may be associated with earlier poor outcome. Further studies evaluating the use of TDI-MPI in longitudinal follow-up of patients with DCM may be helpful in refining its clinical use.
No takes yet. Share an insight, caveat, or question.
Wright et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: